Cost Advantage of Voriconazole over Amphotericin B Deoxycholate for Primary Treatment of Invasive Aspergillosis

Abstract

These data demonstrate the importance of evaluating total drug costs when comparing treatment regimens and not just initial therapy. Initial therapy with voriconazole had a cost advantage over AmBd in total antifungal drug cost/patient.

Pharmacoeconomics of voriconazole in the management of invasive fungal infections

“…Of the 11 evaluations, there were two cost analyses [46,47], two cost-minimization analyses (CMA) [48,49] and seven cost-effectiveness analyses (CEA) [50][51][52][54][55][56][57]. The majority of the studies adopted either a hospital or healthcare perspective, as patients with IA are exclusively treated as in patients.…”

Clinical and economic analysis of voriconazole using for treatment of invasive aspergillosis in Russian Federation

“…В 2 исследованиях, использовавших методику минимизации затрат, было показано, что общие затраты на лечение больных ИА при назначе-нии вориконазола в 1-й линии терапии меньше или равны таковым при назначении амфотерицина B [28,29]. В других исследованиях, изучавших затратную эффективность вориконазола по сравнению с амфо-терицином В, или было показано сокращение затрат при использовании вориконазола (в США, Швейца-рии, Канаде и Нидерландах), или была доказана за-тратная эффективность вориконазола (в Германии) [30][31][32][33][34][35].…”

An update on the pharmacoeconomics of antifungal pharmacotherapy

“…There have been many studies evaluating the cost of AmBd compared with the cost of newer treatment options, such as voriconazole, in patients with invasive aspergillosis [35][36][37][38][39][40][41][42]. All of these cost analyses used data from a multicenter, international, randomized, unblinded trial comparing AmBd with voriconazole for the treatment of invasive aspergillosis in a modifi ed intent-to-treat population [43].…”

“…Another drug-specifi c cost analysis was performed to determine the drug acquisition costs, including the cost of initial therapy (intravenous to oral conversion) and conversion to OLAT, using a Markov model [37]. The average cost of initial treatment, number of patients receiving OLAT, and duration of OLAT therapy was considered for analysis.…”